Human proteins are vulnerable towards disease-associated single amino acid replacements affecting protein stability and function. Interestingly, a few studies have shown that consensus amino acids from mammals or vertebrates can enhance protein stability when incorporated into human proteins. Here, we investigate yet unexplored relationships between the high vulnerability of human proteins towards disease-associated inactivation and recent evolutionary site-specific divergence of stabilizing amino acids. Using phylogenetic, structural and experimental analyses, we show that divergence from the consensus amino acids at several sites during mammalian evolution has caused local protein destabilization in two human proteins linked to disease: cancer-associated NQO1 and alanine:glyoxylate aminotransferase, mutated in primary hyperoxaluria type I. We demonstrate that a single consensus mutation (H80R) acts as a disease suppressor on the most common cancerassociated polymorphism in NQO1 (P187S). The H80R mutation reactivates P187S by enhancing FAD binding affinity through local and dynamic stabilization of its binding site. Furthermore, we show how a second suppressor mutation (E247Q) cooperates with H80R in protecting the P187S polymorphism towards inactivation through long-range allosteric communication within the structural ensemble of the protein. Our results support that recent divergence of consensus amino acids may have occurred with neutral effects on many functional and regulatory traits of wild-type human proteins. However, divergence at † Present address:
Introduction
Through evolution, mutations causing single amino acid replacements may occur and fixate causing beneficial functional and stability changes (adaptive mutations), while others may not show any apparent change on protein functionality (neutral mutations) or affect secondary (promiscuous) functions, while largely deleterious mutations are more rarely fixed (1, 2) . Random mutations are often destabilizing, particularly when they affect the protein core (3) , and may reduce protein stability below a certain threshold impairing functionality and organism fitness, which in principle often prevents their fixation (2) . Fixation of destabilizing mutations can be tolerated if other stabilizing mutations occur before or afterwards (2, 4) . In this context, stability-activity trade-offs can be biologically buffered by different mechanisms, such as control of protein expression and modulation of protein misfolding by molecular chaperones (2, 5) . Importantly, mutations often show pleiotropic effects, manifesting different effects on primary and secondary functions as well as on protein stability (2, 4) . Mutations can also contribute to the evolution of protein function and the acquisition of regulatory mechanisms involving protein allostery through modulation of the dynamics of protein conformational ensembles (1, (6) (7) (8) (9) .
The ability of proteins to fold into a native and stable structure intracellularly is often challenged by mutations, thus leading to disease (10, 11) . During evolution, mammals have gathered a vast network of $1300 different proteins involved in protein biogenesis, folding, trafficking, degradation and maintenance of the proteome named the protein homeostasis network (10, 11) . Mutations may critically affect the ability of proteins to fold and remain stable, causing loss of enzyme function and metabolic defects commonly due to accelerated proteasomal degradation (12) . Global destabilization of the protein structure due to single amino acid replacements may play an important role in this loss-of-function mechanism (13) (14) (15) , although recent studies support the idea that local stability and dynamics of protein structures may drive their directional degradation via the proteasome (15) (16) (17) (18) (19) . Accordingly, small molecules aimed at locally or globally stabilizing protein structure constitute a promising new battery of pharmacological tools to treat these diseases (12, (20) (21) (22) . Mistargeting is another consequence of some mutations (23, 24) , and the compartmentalization of metabolic pathways along evolution (25, 26) seems directly related to such mutations.
Proteins are often stabilized upon replacement of a rare amino acid at a given position by the most common one (i.e. the consensus amino acid) found in an alignment of homologous sequences (27) (28) (29) (30) (31) (32) . These back-to-consensus or consensus mutations increase protein stability primarily by local optimization of the interactions in the environment of the mutated site, and in some cases, by decreasing local flexibility (28, 33, 34) . It has been argued that consensus mutations are reversions to the ancestral amino acid, and thus, their stabilizing effect reflects to some extent the thermophilic nature of ancestral proteins (35) (36) (37) , although the universality of this relationship is unclear (38) . Consensus mutations can act as global intragenic suppressors by providing a stability boost towards destabilizing mutations (39) . Since mammalian and vertebrate consensus amino acids can be strongly stabilizing when incorporated to human proteins (28, 32) , it is intriguing that during the evolutionary history of mammals divergence from consensus amino acids may have yielded some human proteins more prone to loss-of-function and disease-causing mutations.
To investigate the evolutionary divergence of consensus amino acids as potential intragenic suppressors of human disease, we have chosen to study the most common cancerassociated polymorphism (rs1800566/c.C609T/p.P187S) in NAD(P)H:quinone oxidoreductase 1 (NQO1) that causes a Pro187 to Ser187 amino acid replacement (40) . This system is particularly suitable due to the multifunctional nature of this enzyme (allowing us to investigate specific effects on different individual functions) as well as the well-characterized mechanisms by which the polymorphism affects protein function and stability in vivo (18, (41) (42) (43) (44) (45) . NQO1 is a homodimeric FAD-dependent enzyme involved in the activation of some anti-cancer pro-drugs (41, 46) , which also interacts with and stabilizes transcription factors associated with cancer and cell-cycle regulation, such as p53, p73a and HIF-1a (47, 48) . While wild-type (WT) NQO1 is kinetically stable at physiological temperature in vitro (with a denaturation half-life of 9 h), the P187S polymorphism accelerates denaturation by a factor of 60 (43) . More importantly, the P187S polymorphism largely abolishes NQO1 activity in vivo by affecting FAD binding and promotes its proteasomal degradation, through dynamic destabilization of two distant sites: the FAD binding site in the N-terminal domain (NTD, residues 1-224) and the small C-terminal domain (CTD, residues 225-274), respectively (18, 42, 44, 49) . As a consequence, binding of FAD to WT NQO1 protects it towards degradation in vivo while binding of the inhibitor dicoumarol is required to stabilize P187S, supporting a different directionality in their proteasomal degradation (i.e. initiated at the NTD vs. the CTD, respectively) and their specific blockage by ligands affecting protein local dynamics upon binding (18, 44, 45, 49) .
Results
Stabilizing consensus amino acids have been replaced during recent divergent evolution of two diseaseassociated human proteins
To identify consensus mutations for NQO1, we have used an alignment of mammalian sequences, including those with high (over 80%) identity to that of human NQO1 from eighteen different orders overall (Supplementary Materials) and a large representation of those from primates (15.3%), rodents (19.2%), artiodactyla (15.3%), carnivora (11.5%) and chiroptera (9.6%). Among these consensus mutations, H80R causes the most remarkable stabilizing effect either in WT or P187S NQO1 (Fig. 1A  and B and Supplementary Material, Table S1 ), consequently increasing their kinetic stability (i.e. slowing down irreversible inactivation, Supplementary Material, Table S2 ). Importantly, H80R causes a local dynamic stabilization of the N-terminal domain (NTD) of WT NQO1, increasing by 2-fold its resistance towards partial proteolysis by thermolysin ( Fig. 1C and D) , which occurs between Ser72 and Val73 (18) . The H80R mutation has no effect on the sensitivity of P187S towards proteolysis ( Fig. 1C  and D) , showing that the local stabilization of H80R on the NTD does not propagate to the cleavage site of P187S found at its CTD (18) . To provide structural insight for the stabilizing effect of H80R, we have solved the structure of H80R in the presence of FAD and dicoumarol (a competitive inhibitor of NADH; (41)) ( Fig.  1E and F, Supplementary Material, Table S3 ). The presence of the H80R mutation does not affect the overall fold of NQO1, with a RMSD of 0.42 Å (H80R, vs. WT, PDB ID: 2F1O, using PDBeFold (50)), showing two molecules of FAD and dicoumarol per dimer, and a third molecule of the inhibitor is found at the dimer interface (Fig. 1E) . Interestingly, Arg80 undergoes a transition to a less solvent exposed environment than that of His80 (14% vs. 30%), and establishes a salt bridge with Glu78 (at 2.85 Å ) and other electrostatic interactions mainly involving Lys59, and a water molecule (W88) hydrogen-bonded to Glu71 (not present in the WT enzyme; Fig. 1F ). Therefore, this cluster of electrostatic interactions mostly involving Glu71, Glu78 and Arg80 (hereafter named the 'EER' cluster) appears to be critical for the local stabilization exerted by H80R. Importantly, the EER cluster seems to stabilize the adjacent loop 57-66, which is highly dynamic in the P187S polymorphism and involved in its lower affinity for FAD (18) .
Arg80 is found in most of the closely related mammalian sequences, suggesting that its stabilizing effect has disappeared recently in an evolutionary time scale. Specifically, this implies that the stabilizing effect of the consensus state at this position (i.e. Arg80) was present in mammalian ancestors of NQO1 and recently diverged to the non-consensus state found in the human enzyme (Fig. 2) . Consequently, Arg80 is present in rat NQO1, and its available X-ray crystal structure allows direct comparison of the structural consequences of the His-to-Arg transition in these orthologues with high (85%) sequence identity. Structural superposition of human WT and H80R enzymes with rat NQO1 show that the local structural switch triggered by Arg80 in the human enzyme is found in the murine enzyme ( Fig. 2A and B) . In addition, the EER cluster is also structurally conserved in the murine protein, and Arg80 causes a similar local stabilization of the structure to that found in human H80R. The electrostatic local stabilization due to the EER cluster amounts to -1.8 and -2.3 kcalÁmol À1 for human H80R and rat NQO1 compared to the human WT enzyme (Fig. 2C) . Overall, Arg80 develops more stabilizing electrostatic interactions with its environment in rat than in human NQO1 ( Fig. 2C and D) , mostly due to the presence of a non-conserved Glu59 in the rat enzyme which is a Lys in human NQO1 and most of the mammalian sequences. Nevertheless, a comparison of pairwise electrostatic interactions within the EER cluster (including Lys/ Glu59), clearly shows that the local stabilizing role of the EER cluster found in human NQO1-H80R is present in the rat enzyme (Fig. 2D ). This EER cluster contains the largely stabilizing Arg80 in most of mammalian sequences of different orders, including different primate families, but sharply shifts to His80 in the hominidae family ( Fig. 2E and F) , indicating that the Arg-toHis mutation has been recently fixed along primate evolution. Ancestral sequence reconstruction indicates that the Arg-to-His transition likely occurred after divergence of Cercopithecoidea and Hominoidea superfamilies from a common ancestor about 30 Myr ago (Fig. 2G) .
To test whether similar events to the recent Arg-to-His transition at position 80 in mammalian NQO1 may have occurred in other consensus amino acids as well as for other proteins, we have performed consensus analyses using essentially the same set of mammalian species for NQO1 with human alanine:glyoxylate aminotransferase 1 (hAGT). hAGT is associated, due to inherited mutations and the polymorphism P11L, with the life-threating disease primary hyperoxaluria type I (OMIM #259900), in which genetic variations cause loss-of-function of hAGT activity notably due to protein mitochondrial mistargeting and peroxisomal aggregation (23, 24) . We have recently performed a detailed characterization of the effect of consensus mutations in hAGT, including quantitative stability and structural analyses for single-and multiple-consensus mutants (28) . As shown in Figure 3A , consensus analyses reveal a similar set of stabilizing mutations to that previously found using somewhat different groups of mammalian and eukaryotic sequences and experimentally validated for hAGT (28) . Interestingly, murine orthologues of human NQO1 and hAGT (for which there are X-ray structures) display a large fraction of these consensus amino acids (Fig. 3B) .
Detailed sequence, phylogenetic and structural analyses support the proposal that the fixation of a non-consensus (potentially disease-predisposing) amino acid in human NQO1 (i.e. His80) is not an unusual or isolated event (Fig. 3 , Supplementary Materials, Figs. S1 and S2). Consensus amino acids are found in mammalian sequences with very high identity to the human orthologue, and divergence at these sites and consequent loss of stability seem to have occurred particularly along primate evolution ( Fig. 3B and C) . Indeed, ancestral sequence reconstruction analyses support that about 70-80% of the mammalian consensus amino acids analysed in NQO1 and AGT have been progressively replaced through the last 40 Myr (Fig. 3D) .
Our interpretation on the loss of stability due to divergence from consensus amino acids implies that their stabilizing effects on human NQO1 (this work) and hAGT (28) are conserved between highly similar orthologue proteins, a plausible assumption considering that site specific amino acid preferences are often highly conserved along evolution (39, 51) . The available crystal structures for human and murine enzymes containing consensus amino acids at these sites provide further structural and energetic support for the interspecies conservation of the local stabilization exerted by consensus amino acids. Human and murine WT proteins, as well as human enzymes containing a single (NQO1-H80R) or multiple (hAGT-RHEAM) consensus mutations share the overall fold (Supplementary Materials, Figs S1A and S2A). In human NQO1, all six consensus mutations are individually stabilizing ( The consensus mutation H80R rescues P187S NQO1 activity intracellularly through local stabilization of the FAD binding site without affecting the interaction with p73a
To test whether mammalian consensus amino acids can act as suppressors of disease phenotype, we have further investigated the mutation H80R in the presence of the cancer-associated P187S NQO1 polymorphism. Notably, the local stabilization exerted by H80R at the NTD affects the environment of the FAD binding site (Fig. 4A) , whose destabilization by P187S in the apostate (particularly at the loop 57-66) causes enzyme inactivation by reducing the affinity for FAD (18) . Accordingly, H80R increases the content in FAD of P187S as purified (Fig. 4B) , causing a concomitant large increase in specific activity (Fig. 4C ) without perturbing other kinetic properties (e.g. the apparent affinities for NADH and DCPIP as substrate; Supplementary Materials, Table S4 and Fig. S3 ). Results from thermal denaturation experiments with an excess of FAD ruled out that the stabilizing effect of H80R on P187S is due to the presence of higher FAD levels in the proteins as purified (Supplementary Material, Fig. S4 ). Local stabilization of the FAD binding site of P187S by H80R also translates into a 10-fold higher binding affinity for FAD, with little consequence on the WT enzyme, as shown by fluorescence titrations (Fig. 4D, Supplementary Material, Fig. S5 ). Molecular dynamics (MD) simulations recapitulate the structural switch caused by H80R (Supplementary Material, Fig. S6 ) further showing that this switch dynamically stabilizes the loop 57-66, particularly in the apo-state of P187S ( Fig. 4E and F) . The local stabilization exerted by H80R on the NTD should increase the FAD binding affinity of P187S, and consequently its activity inside cells, without affecting degradation rates or protein levels (which are largely influenced by the dynamic CTD; (18)). We have thus investigated the effects of H80R on the intracellular activity, protein levels and degradation rates of WT and P187S by combining experiments in stably transfected Caco-2 cells (showing low endogenous levels of NQO1 protein due to being homozygous for P187S; (18)) with pulse-chase experiments in a rabbit reticulocyte cell-free system (Fig. 4G-K) . Western-blot analysis of transfected Caco-2 cells reveal a 3-fold increase in protein levels of P187S in the presence of the suppressor H80R mutation, while this effect is weak in WT NQO1 (1.4-fold increase; Fig. 4G and H) . The levels of endogenous NQO1 P187S in Caco-2 cells (lower immunodetected bands in Fig. 4G ) are somewhat higher when cells are transfected with NQO1 variants containing the H80R mutation, suggesting that the presence of this mutation favors hetero-oligomerization between exogenous (i.e. transfected) and endogenous P187S NQO1. Since degradation of NQO1 proteins upon expression in rabbit reticulocyte extracts is mediated by the proteasome (52), we have used this system to determine whether H80R affects proteasomal degradation rates. The obtained results show that H80R has little effect on the degradation rates of WT and P187S (Fig. 4I) , suggesting that the effect of H80R on intracellular protein levels of P187S reflects an improved intracellular folding efficiency. Functional rescue of P187S by H80R is further supported by measurements of NQO1 activity in transfected cell extracts using DCPIP as substrate (Fig. 4J) and corroborated by the increased capacity of intact transfected cells to activate the drug 17-AAG (17-N-allylamino-17-demethoxygeldanamycin) into its cytotoxic form (53) (Fig. 4K, Supplementary Material, Fig.  S7 ). Importantly, NQO1 activity measurements (Fig. 4J and K) correlate well with the levels of transfected NQO1 proteins ( Fig.  4G and I) , supporting that hetero-oligomerization of transfected proteins with endogenous P187S plays a minor role in the functional rescue exerted by H80R on P187S.
So far, we have shown that the consensus H80R mutation is capable of reactivating P187S NQO1 to a significant extent in vitro and in cells likely due to enhanced FAD binding affinity and folding efficiency. To determine whether this consensus mutation might affect further functions, such as their ability to interact with transcription factors (e.g. p73a), we have used NMR spectroscopy to investigate binding of NQO1 variants with the C-terminal domain of p73a (SAMp73a) (49) . Even though small quantitative differences are observed between NQO1 variants, these analyses support that the core of the residues involved in NQO1:SAMp73a interaction is not greatly affected by the H80R mutation (Supplementary Materials, Fig. S8 and Table S5 ).
E247Q cooperates with H80R to rescue NQO1 P187S through long-range epistatic interactions
During the evolution of proteins, the effects of a single mutation often depend on the presence of additional mutations (a type of epistatic interactions; (2,4) ). In the context of this work, divergence from consensus amino acids at different sites in a short evolutionary time period (see Fig. 3 ), may have cooperated to enhance the sensitivity of human NQO1 and AGT towards disease-associated inactivation through this type of interactions. This cooperation is further expected from the additive effects of consensus mutations on protein stability (28, 30, 54) . To test this hypothesis, we have characterized the effects of the consensus NQO1 mutation E247Q, in the absence or presence of H80R (Fig. 5) . These two sites are not spatially close (at $40 Å ) and the Glu247 is also far from the FAD binding site (at $25 Å ; Fig. 5A ). We found that E247Q locally stabilizes the CTD of P187S, decreasing by 2-fold the sensitivity to partial proteolysis, and its effects propagate to the distal NTD enhancing the local stabilization exerted by H80R in the WT enzyme (Fig. 5B) . This long-range communication of the stabilizing effect of E247Q concomitantly increases the FAD content and specific activity of P187S, boosting the effects of H80R (Fig. 5C and D) . FAD titrations confirmed stronger binding of FAD to P187S in the presence of E247Q, particularly in combination with H80R (Fig. 5E,  Supplementary Material, Fig. S5 ), while very tight FAD binding was found for all variants of WT NQO1 (Fig. 5F, Supplementary  Material, Fig. S5 ). As described earlier in this work for H80R, the presence of E247Q did not largely affect the core of residues in SAMp73a involved in the formation of its complex with NQO1 (Supplementary Materials, Fig. S8 and Table S5 ).
These results demonstrate that the additive stabilizing effects of consensus mutations can propagate to distal functional sites, in line with our recent findings on the long-range communication existing between the Pro187 site, the FAD binding site and the CTD, in particular when the CTD is withdrawn (49) . Surprisingly, the epistastic effects described here for H80R and E247Q mutations support directionality in their propagation (in agreement with some ensemble descriptions of allosteric mutational effects; see (55)): the H80R mutation locally stabilizes the NTD, with no apparent effects on the stability or dynamics of the CTD (Fig. 1C and D) , while the E247Q mutation stabilizes the CTD and the distal NTD, and importantly, enhances the local stabilization exerted by H80R on the NTD (Fig. 5B ).
Discussion
We have provided evidence supporting that consensus amino acids among mammalian sequences have diverged over the last 50 Myr, decreasing the local stability of some human proteins and potentially predisposing them towards disease-associated, destabilizing and inactivating single amino acid changes. Due to the conservation of the stabilizing effect of consensus amino acids, at least in protein orthologues with highly similar sequences, their additive effects on stability, and the existence of long-range epistatic interactions between some consensus amino acids, it is intriguing to propose that some extant mammalian proteins (such as those from rodents) might be more robust towards disease-associated and destabilizing single amino acid replacements. Importantly, we demonstrate the potential of consensus amino acids to protect towards disease-associated single amino acid changes. This case also exemplifies well how deeply evolution can affect the protein conformational landscape through single mutations altering protein functionality in vivo, and particularly, the key role of long-range propagation of structural and dynamic effects to different functional sites. An interesting application of consensus mutations as disease suppressors could be the identification of druggable spots in proteins, i.e. to mimic the suppressor effect of the mutation using small pharmacological ligands.
From the perspective of natural selection, it is difficult to conceive how destabilizing mutations diverging from consensus amino acids are fixed along evolution, unless the mutated sites are under low selective pressure. In this case, mutations diverging from the consensus amino acid would be eventually fixed if they have little or no effect on protein function in vivo (or ultimately, in the reproductive capacity of the species), therefore constituting networks of neutral mutations (or neutral networks; (2)). Indeed, this neutral network scenario explains well the experimentally observed effects on human NQO1 and AGT proteins (this work and (28)). In the case of NQO1, a paradigm of multi-functional stress protein, mutation of the consensus Arg80 (to His) and Gln247 (to Glu) have little or no effect in many different molecular traits, such as its specific activity, FAD content, intracellular stability and folding efficiency, or interaction with p73a. For human AGT, the simultaneous absence of up to five consensus amino acids only slightly affects its specific activity and has no impact on the intracellular folding, stability and peroxisomal import upon interaction with the peroxisomal receptor Pex5p (28) . It can also be argued that the divergence of some consensus amino acids in these human proteins has been driven by natural selection, for instance by fine-tuning of some intracellular functions, unfortunately not yet identified by the functional analyses performed so far.
Our results with NQO1 have also important implications for understanding the stability and dynamics of the human flavoproteome. A recent comprehensive proteomic analysis has shown that the stability of human flavo-proteins is strongly dependent on the bioavailability of the flavin cofactor, and NQO1 has emerged as a particularly sensitive case (45) . Our results further highlight the importance of the apo-state ensemble, in particular its structure, stability and dynamics (18, (42) (43) (44) (45) 49, 56) , in determining the cofactor binding affinity of human flavoproteins, and consequently, their function and stability in vivo. This can be of particular relevance to understand the large number of metabolic diseases associated with flavo-proteins (linked to about 60% of all human flavo-proteins, based on a recent and exhaustive analysis (57)), and the significant fraction of them associated with riboflavin supplementation (57, 58) .
Materials and Methods

Consensus and phylogenetic analyses
The sequences of mammalian NQO1 and AGT enzymes were retrieved using BlastP and the human sequences as queries. This set of sequences (see Supplementary Materials) was used to identify consensus amino acids as those displaying the highest frequencies in the alignment. Therefore, the consensus ratio was defined as the number of sequences containing the most common amino acid in the alignment divided by the number of sequences containing the amino acid found in the human protein at the same site. In NQO1, the six consensus mutations displaying consensus ratios higher or equal to 5 were selected for further characterization.
Phylogenetic trees based on the sequences of the NQO1 and AGT proteins were made according to the UPGMA method with the phangorn package (59) from the gnu-R statistical software. Analysis of time divergence was performed according to (60, 61) .
Materials
Antibiotics, HEPES, cacodylate, KOH, DCPIP, FAD, NADH and thermolysin from Bacillus thermoproteolyticus rokko were purchased from Sigma Aldrich (Madrid, Spain). Chromatographic columns for protein purification were from GE Healthcare (Barcelona, Spain). Concentration devices (cut offs of 3-30 kDa) were from Millipore (Madrid, Spain) or Sartorius (Madrid, Spain). Other chemicals were purchased from standard suppliers.
Mutagenesis, expression and purification of NQO1 variants in E. coli Site-directed mutagenesis was performed using the QuickChange lightening kit (Agilent Technologies, Madrid, Spain) by standard protocols and confirmed by sequencing. Expression in and purification from E. coli BL21 (DE3) was performed as described (43) .
In vitro characterization of NQO1 proteins NQO1 activity was measured by following the reduction of DCPIP as described (49) . FAD content in purified NQO1 samples was estimated from UV-visible absorption spectra. Briefly, NQO1 proteins in K-HEPES 50 mM pH 7.4 were prepared $0.6 mgÁmL À1 and the absorption spectra registered in a HP 8453 spectrophotometer (Agilent) at 25 C. The corresponding spectra were converted into molar extinction units using a corrected extinction coefficient at 280 nm for each purified NQO1: (43)).
This procedure yields estimates for the FAD content in purified samples by using a reference value of e 450 ¼ 11300 M
À1
Ácm À1 for 100% saturation. Thermal denaturation of NQO1 proteins was determined in K-HEPES 50 mM pH 7.4 at a protein concentration of 2 mM in the presence of the fluorescent probe SYPRO Orange (Life Technologies, Madrid, Spain). Thermal scans were registered in a IQ5 Real-time PCR detection system (Biorad, Madrid, Spain) by monitoring fluorescence upon excitation at 460 nm and emission at 510 nm at a scan rate of 0.5 CÁmin
. The melting temperature was determined from the maximum of the first derivative (T der ) or as the half-denaturation temperature upon normalization of the unfolding curves (T 0.5 ) as described (21) . Additionally, thermal stability of NQO1 proteins in the absence or presence of FAD (2 mM NQO1 monomer and 10 mM FAD) was determined by following intrinsic fluorescence (exc. 280 nm, em. 340 nm; slits 5 nm) in K-HEPES 50 mM pH 7.4. Thermal scans were registered using 0.3 cm path-length quartz cuvettes in a Cary-Eclipse spectrofluorimeter (Agilent Technologies), using 2 CÁmin À1 scan rate and T m values determined as described above (T 0.5 procedure). Data are reported as mean 6 s.d. from three independent scans. Inactivation kinetics was determined by incubation of protein samples (40 lM) for different times at 42 C, chilling on ice and measurement of residual activity as described (49) . Proteolysis kinetics by thermolysin were performed as recently described (18) . Protease concentration was 100-200 nM (WT variants) or 0.5-1 nM (P187S variants). For each variant, two independent experiments were performed and data of intact NQO1 protein vs. time decays were used to determine firstorder rate constants from exponential fits. These constants were divided by the thermolysin concentration used to yield second-order proteolysis rate constants (k prot ). For sake of comparison, ratios of k prot value for WT and the corresponding variant are provided, which indicate a stabilizing effect when these are larger than one and a destabilizing effect when lower than one.
Fluorescence titrations were performed at 25 C using 1 cm path-length cuvettes in a Cary Eclipse spectrofluorimeter (Agilent Technologies) and a final volume of 2 ml. FAD was prepared in K-HEPES 50 mM pH 7.4 (at a final concentration 0-5 lM) in 1.9 ml and incubated for 5 min in the cuvette while the fluorescence of these blanks (exc. 295 nm; em.: 340 nm; slits 5 nm) was registered. Then, 100 ll of apo-NQO1 (4 lM in monomer) was added, manually mixed, and fluorescence was measured for 10 min to ensure proper equilibration. The fluorescence intensity of the last 60 s was averaged and the signal of the blank without protein was subtracted. Control experiments in the absence of FAD showed that apo-NQO1 did not significantly denature under these experimental conditions. For each protein variant, at least two different protein preparations and FAD stock solutions were used. K d values were determined from fittings to 1:1 binding model using the following expression:
where F is the fluorescence intensity of the sample at a given total FAD concentration ([FAD]), F holo and F apo are the intensities of the holo-and apo-proteins and [E] is the total concentration of NQO1 (0.2 lM in monomer). In all cases, fittings using this model provided a good description of the experimental data within the experimental uncertainty (Supplementary Material, Fig. S5 ). The interaction of NQO1 and SAMp73a was investigated by NMR spectroscopy. NMR data were acquired at 20 C on a
Bruker Avance DRX-500 spectrometer equipped with a tripleresonance probe and z-gradients. Samples containing NQO1 proteins (at $300 lM, in monomer units) and 15 N-labelled SAMp73a ($120 lM) were prepared in 50 mM phosphate buffer pH 6.9. The 2D (62) were acquired in the phase sensitive mode. Experiments were acquired and analysed as described (49) .
Crystallography
Crystallization trials were carried out via the hanging-drop vapour diffusion method using previously reported conditions (63) at pH 7-9 and crystal improvement was achieved by the capillary counter diffusion technique (64) set-up using the Domino Granada Crystallization Boxes V R (Triana Science & Technology, Granada, Spain). Good quality diffracting crystals were obtained using 30% of PEG 3350, 200 mM sodium acetate, 100 mM sodium tricine pH 9.0, 1% DMSO and 10 mM dicoumarol, as precipitant agent. NQO1 H80R (70 mgÁml
À1
) mixed with agarose (0.05% w/v) was used to fill capillaries of 0.2 mm inner diameter. Crystals were equilibrated for 24 h with the mother liquid supplemented with 15% (v/v) glycerol before being extracted from the capillaries and flash-cooled in liquid nitrogen. Data were collected at ID-29 beam-line of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) from flashed cooled crystals. Data were indexed and integrated using XDS (65) and scaled with SCALA from the CCP4 suite (66) . The structure was determined by molecular replacement using the structure of WT NQO1 (PDB: 1D4A) without waters, as search model. The molecular replacement solution was found using Phaser (67) locating the two monomers in the asymmetric unit. Structure refinement was done with phenix.refine (68) with cycles of manual building steps and ligand identification performed with Coot (69). Titration-Libration-Screw (TLS) was included in the last steps of refinement. Model quality was checked using MolProbity (70) implemented within the Phenix suite (68 
Electrostatic calculations
Calculation of the energy of charge-charge interactions (E q-q ) was performed using the solvent-accessibility-corrected Tanford-Kirkwood model (72) . The input for these calculations were the atomic coordinates of: human NQO1 WT (2F1O) and H80R (2FUQ), rat NQO1 (1QRD), human AGT WT (1H0C) and RHEAM (4CBS), and mouse AGT (3KGX). We used an in-house software (kindly provided by Prof. Jose Manuel Sanchez-Ruiz, Department of Physical Chemistry, University of Granada) at pH 7.4 and 0.025 M (for NQO1) or 0.2 M (for AGT) ionic strength. The output of these analyses provides the energy of charge-charge interactions of a given ionizable residue with all or individual ionizable residues in the protein dimer, and are expressed per ionizable residue.
MD simulations
MD simulations were performed as recently described for WT and P187S NQO1 (18) . The structures containing the mutation H80R were prepared using MOE (73) based on a crystal structure of the NQO1 complex with FAD (PDB: 1D4A) (63) . The side-chain of Arg80 was modelled using two distinct conformations, solvent-exposed and partially buried. Nevertheless, after an extensive equilibration protocol (74) and a 100 ns sampling simulation, we observed a consistent orientation for Arg80 in the buried state after few ns. Analyses of MD trajectories were performed as recently described (18) .
NQO1 expression in Caco-2 cells
Caco-2 cells were grown and maintained in Dulbecco's Modified Eagle Medium (Lonza, Barcelona, Spain) supplemented with 10% heat inactivated fetal bovine serum (HyClone, GE Healthcare, Barcelona, Spain), 100 UÁml À1 penicillin and 100 mgÁml À1 Streptomycin (Sigma Aldrich, Madrid, Spain) and cultured at 37 C in a humidified incubator with 5% CO 2 . Cells were transfected using Lipofectamine LTX with Plus Reagent (Thermo Fisher Scientific, Madrid, Spain) according to manufacturer's protocol and pCINeo plasmids containing the cDNA of NQO1 enzymes and selected using 400 mgÁml À1 of G418 (Sigma Aldrich) for a month. For immunoblotting, cells were scrapped and lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Triton X-100, 0.1% sodium dodecyl sulphate, 1 mM sodium orthovanadate, 1 mM NaF pH 8) with protease inhibitors (COMPLETE, from Roche, Spain). After centrifugation at 20000 g for 30 min, soluble extracts were collected and the amount of total protein determined by the BCA method (Pierce). Samples were denatured with Laemmli's buffer under reducing conditions, resolved using 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes (GE Healthcare) using standard procedures. Immunoblotting was carried out using primary monoclonal antibodies anti-NQO1 and anti-b-actin (Santa Cruz Biotechnology) from mouse at 1:500 and 1:10000 dilutions, respectively. As a secondary antibody, we used chicken antimouse IgG-HRP (Santa Cruz Biotechnology) at 1:2000 dilution. Protein bands were visualized using luminol-based enhanced chemiluminiscence and images were acquired with ChemiDoc MP imaging system and analysed using Image Lab 5.0 software (both from BioRad Laboratories).
For NQO1 activity measurements, cells were collected in 50 mM K-HEPES pH 7.4 with protease inhibitors (COMPLETE, Roche) and lysed by freezing-thawing cycles. Soluble extracts were obtained upon centrifugation at 18000 g for 15 min at 4 C and total protein content was determined by the BCA method (Pierce) and immediately used for measurements. Activity measurements were carried out as described (18, 49) using DCPIP (75 lM) as electron acceptor and 0.5 mM NADH. Upon blank subtraction, the activity was normalized by the amount of total protein used in each measurement (50-130 lg). NQO1 expression in a cell-free system
Pulse-chase experiments were performed using a TnT rabbit reticulocyte cell-free system (Promega, Madrid, Spain) at 30 C as described in (49) .
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